
PERSONAL PARTICULARS

Surname: Vahid Shaygannejad

Date of birth: 1968/01/02

Place of birth: Isfahan

Country of birth: Iran

Nationality: Iranian

Marital Status: Married

Children: 2

Address: Alzahra Hospital, Isfahan, Iran

Residence: Isfahan

Phone: +9836291050

E-mail: shaygannejad@med.mui.ac.ir



ACADEMIC TRAINING AND EDUCATION

2008 Postdoctoral Fellow, Multiple Sclerosis Center, Department of Neurology, University of Ottawa, Canada.

1996 -2000 Postdoctoral Neurology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

1985-1992 Medical Doctor (M.D.), Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

1983-1985 Pre-university course in Biology, Adab, Isfahan, Iran.

1982-1985 High school diplomas in Adab High School. Isfahan, Iran.

PROFESSIONAL AND OTHER COURSES

2013 Epidemiology of Multiple Sclerosis. At "Epidemiology and Immunology of Multiple Sclerosis conference" for Ph.D by Research students, Kashani Hospital, medicine faculty, Isfahan University of Medical Sciences, Isfahan, Iran

2013 Neuroimaging of Multiple Sclerosis. At "Seminar on recent advances in Multiple Sclerosis", Radiology Conference Hall, Al-Zahra hospital, Soffeh street, Isfahan, Iran

ACADEMIC HONORS AND AWARDS

1992 Top student of medicine faculty, Awarded by the Dean of medicine faculty, Isfahan University of Medical Sciences, Isfahan, Iran

2000 First ranked neurology resident in the national board exam of neurology in Iran.

2012 Third ranked special award for researcher at Isfahan University of Medical Sciences, Isfahan, Iran

EXECUTIVE ACTIVITIES

- Head of Isfahan Neurosciences Research Center
- Head of MS clinic in Isfahan Kashani Hospital

ATTENDED CONFERENCES AND WORKSHOPS

I have presented aspects of my research in the form of both oral and poster communications at various major national and international conferences which given as below.

EDITORIAL WORK & GRANT and JOURNAL REVIEWER

EDITORIAL BOARD MEMBER; Advanced Biomedical Research Journal

JOURNAL REVIEWER FOR:

- Journal of Research in Medical Sciences
- International Journal of Preventive Medicine
- Advanced Biomedical Research Journal
- ARYA Atherosclerosis
- Iranian journal of neurology
- National Institute for Medical Research Development (NIMAD)

GRANT REVIEWER FOR:

- International Journal of Preventive Medicine

QUALIFICATIONS AND SKILLS

LINGUISTIC COMPETENSE

Persian Excellent (First native language)
English Excellent (Second language)

LIST OF PUBLICATIONS

<p>Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult.</p> <p>Ziaei A, Garcia-Miralles M, Radulescu CI, Sidik H, Silvin A, Bae HG, Bonnard C, Yusof NABM, Ferrari Bardile C, Tan LJ, Ng AYJ, Tohari S, Dehghani L, Henry L, Yeo XY, Lee S, Venkatesh B, Langley SR, Shaygannejad V, Reversade B, Jung S, Ginhoux F, Pouladi MA. <i>Brain Pathol.</i> 2022 Mar 13:e13064. doi: 10.1111/bpa.13064. Online ahead of print.</p>	2022
<p>Radiologically Isolated Syndrome: An Atypical Presentation of Balo's Concentric Sclerosis in a Patient with the Meniere's Disease.</p> <p>Nouri H, Mirmosayyeb O, Badihian S, Shaygannejad V. <i>Neurol India.</i> 2022 Jan-Feb;70(1):439-440. doi: 10.4103/0028-3886.338680.</p>	2022
<p>Bell's palsy after Sputnik V COVID-19 (Gam-COVID-Vac) vaccination.</p> <p>Mirmosayyeb O, Barzegar M, Rezaei M, Baharlouie N, Shaygannejad V. <i>Clin Case Rep.</i> 2022 Feb 23;10(2):e05468. doi: 10.1002/ccr3.5468. eCollection 2022 Feb.</p>	2022
<p>Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.</p> <p>Askari M, Mirmosayyeb O, Ghaffary EM, Ghoshouni H, Shaygannejad V, Ghajarzadeh M. <i>Mult Scler Relat Disord.</i> 2022 Feb 9;59:103680. doi: 10.1016/j.msard.2022.103680. Online ahead of print.</p>	2022
<p>Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset.</p> <p>Sadeghi-Bahmani D, Barzegar M, Mirmosayyeb O, Vaheb S, Nehzat N, Shaygannejad V, Brand S. <i>J Clin Med.</i> 2022 Jan 29;11(3):734. doi: 10.3390/jcm11030734.</p>	2022
<p>COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.</p> <p>Barzegar M, Mirmosayyeb O, Ebrahimi N, Bagherieh S, Afshari-Safavi A, Hosseinabadi AM, Shaygannejad V, Asgari N. <i>Mult Scler Relat Disord.</i> 2022 Jan;57:103359. doi: 10.1016/j.msard.2021.103359. Epub 2021 Nov 1.</p>	2022
<p>COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.</p>	2022

<p>Naghavi S, Kavosh A, Adibi I, Shaygannejad V, Arabi S, Rahimi M, Mazaheri S, Ashtari F. <i>Mult Scler Relat Disord</i>. 2022 Jan;57:103335. doi: 10.1016/j.msard.2021.103335. Epub 2021 Oct 16.</p>	
<p>Incidence, prevalence, and characteristics of heart failure among patients with multiple sclerosis: A systematic review and meta-analysis.</p> <p>Bagherieh S, Ghoshouni H, Bostan F, Afshari-Safavi A, Badihian S, Barzegar M, Shaygannejad V, Mirmosayyeb O. <i>Mult Scler Relat Disord</i>. 2022 Feb 4;59:103665. doi: 10.1016/j.msard.2022.103665. Online ahead of print.</p>	2022
<p>Comparison of susceptibility weighted imaging with conventional MRI sequences in multiple sclerosis plaque assessment: A cross-sectional study.</p> <p>Rabbani M, Shaygannejad V, Bahrami M, Badiei S. <i>J Res Med Sci</i>. 2021 Dec 22;26:128. doi: 10.4103/jrms.JRMS_726_17. eCollection 2021.</p>	2021
<p>Prevalence of trigeminal neuralgia in multiple sclerosis: A systematic review and meta-analysis.</p> <p>Houshi S, Tavallaei MJ, Barzegar M, Afshari-Safavi A, Vaheb S, Mirmosayyeb O, Shaygannejad V. <i>Mult Scler Relat Disord</i>. 2022 Jan;57:103472. doi: 10.1016/j.msard.2021.103472. Epub 2021 Dec 29.</p>	2021
<p>The Serum Level of Midkine in Patients With Multiple Sclerosis and Neuromyelitis Optica.</p> <p>Moayednia M, Dehghani L, Safi A, Shaygannejad V, Sohrabi K, Rezvani M, Akrami MR, Soghрати M, Aboutalebi MM, Barzegar M. <i>Basic Clin Neurosci</i>. 2021 Mar-Apr;12(2):199-204. doi: 10.32598/bcn.12.2.1009.2. Epub 2021 Mar 1.</p>	2021
<p>The Effect of Emotional Freedom Technique on Fatigue among Women with Multiple Sclerosis: A Randomized Controlled Trial.</p> <p>Ghaderi Z, Nazari F, Shaygannejad V. <i>Iran J Nurs Midwifery Res</i>. 2021 Oct 22;26(6):531-536. doi: 10.4103/ijnmr.IJNMR_188_19. eCollection 2021 Nov-Dec.</p>	2021
<p>Characteristics of COVID-19 in patients with multiple sclerosis.</p> <p>Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi Langroodi H, Baghbanian SM, Mozhdhipanah H, Majdi-Nasab N, Hosseini S, Poursadeghfard M, Beladimoghadam N, Razazian N, Ayoubi S, Rezaeimanesh N, Eskandarieh S, Naser Moghadasi A. <i>Mult Scler Relat Disord</i>. 2022 Jan;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30.</p>	2021

<p>The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients.</p> <p>Karimi L, Eskandari N, Shaygannejad V. <i>Neuroimmunomodulation</i>. 2021 Nov 22;1-9. doi: 10.1159/000519777. Online ahead of print.</p>	2021
<p>Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis.</p> <p>Mirmosayyeb O, Shaygannejad V, Bagherieh S, Hosseinabadi AM, Ghajarzadeh M. <i>Neurol Sci</i>. 2022 Jan;43(1):233-241. doi: 10.1007/s10072-021-05750-w. Epub 2021 Nov 17.</p>	2021
<p>Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study.</p> <p>Seyed Ahadi M, Sahraian MA, Shaygannejad V, Anjidani N, Mohammadiani Nejad SE, Beladi Moghadam N, Ayromlou H, Yousefi Pour GA, Yazdanbakhsh S, Jafari M, Naser Moghadasi A. <i>Caspian J Intern Med</i>. 2021;12(Suppl 2):S491-S494. doi: 10.22088/cjim.12.0.491.</p>	2021
<p>Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].</p> <p>De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofri M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. <i>Comput Methods Programs Biomed</i>. 2022 Jan;213:106479. doi: 10.1016/j.cmpb.2021.106479. Epub 2021 Nov 5.</p>	2021
<p>Managing anxiety among multiple sclerosis patients during COVID-19 pandemic.</p> <p>Adibi I, Mirmosayyeb O, Ramezani N, Shaygannejad V. <i>J Res Med Sci</i>. 2021 Aug 30;26:68. doi: 10.4103/jrms.JRMS_633_20. eCollection 2021.</p>	2021
<p>Acute CNS demyelination in a subject with cerebellar ataxia following the first dose of COVID-19 vaccine; a case report.</p> <p>Mirmosayyeb O, Bagherieh S, Shaygannejad V. <i>Hum Vaccin Immunother</i>. 2021 Nov 2;17(11):4099-4101. doi: 10.1080/21645515.2021.1971920. Epub 2021 Oct 29.</p>	2021

<p>The prevalence of Myocardial Infarction among Multiple Sclerosis Patients: a Systematic Review and Meta-analysis.</p> <p>Tavallaei MJ, Tavallaei AH, Ebrahimi N, Ghoshouni H, Afshari-Safavi A, Badihian S, Shaygannejad V, Mirmosayyeb O. <i>Mult Scler Relat Disord.</i> 2021 Nov;56:103292. doi: 10.1016/j.msard.2021.103292. Epub 2021 Sep 30.</p>	
<p>Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis.</p> <p>Imani SZH, Hojati Z, Khalilian S, Dehghanian F, Kheirollahi M, Khorrami M, Shaygannejad V, Mirmosayyeb O. <i>Sci Rep.</i> 2021 Sep 28;11(1):19260. doi: 10.1038/s41598-021-98691-5.</p>	2021
<p>Paraparesis due to aortic thromboembolism as a rare complication of COVID-19 infection.</p> <p>Motahharynia A, Naghavi S, Shaygannejad V, Adibi I. <i>J Vasc Surg.</i> 2021 Sep;74(3):1047. doi: 10.1016/j.jvs.2021.04.062.</p>	2021
<p>Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.</p> <p>Nehzat N, Mirmosayyeb O, Barzegar M, Vosoughi R, Fazeli E, Shaygannejad V. <i>Neurol Res Int.</i> 2021 Jul 15;2021:6679197. doi: 10.1155/2021/6679197. eCollection 2021.</p>	2021
<p>Quantitative Magnetic Resonance Imaging Analysis of Early Markers of Upper Cervical Cord Atrophy in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.</p> <p>Adibi I, Najafi A, Merajifar F, Ramezani N, Nouri H, Jalilvand N, Ashtari F, Vard A, Shaygannejad V. <i>Mult Scler Int.</i> 2021 Jul 9;2021:9917582. doi: 10.1155/2021/9917582. eCollection 2021.</p>	2021
<p>Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS).</p> <p>Mirmosayyeb O, Barzegar M, Afshari-Safavi A, Nehzat N, Heidari A, Emami P, Shaygannejad V. <i>Mult Scler Int.</i> 2021 Jun 10;2021:8874999. doi: 10.1155/2021/8874999. eCollection 2021.</p>	2021
<p>Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.</p>	2021

Doosti R, Naser Moghadasi A, Azimi AR, Karbalai Saleh S, Etemadifar M, Shaygannejad V, Ashtari F, Harirchian MH, Siroos SB, Ayramloo H, Majdinasab N, Hojjati SMM, Asghari N, Baghbanian SM, Cheraghmakani H, Abedini M, Sedighi B, Mohseni Abbas Abadi N, Ghasemitabar M, Talebianpour S, Babayi Daylari T, Dana V, Ghaleh Noie N, Sahraian MA. <i>Caspian J Intern Med</i> . 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263.	
Early predictors of conversion to secondary progressive multiple sclerosis. Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, Mirmosayyeb O, Shaygannejad V. <i>Mult Scler Relat Disord</i> . 2021 Sep;54:103115. doi: 10.1016/j.msard.2021.103115. Epub 2021 Jun 26.	2021
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. Moradi N, Sharmin S, Malpas C, Ozakbas S, Shaygannejad V, Terzi M, Boz C, Yamout B, Turkoglu R, Karabudak R, Hamdy S, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T; MSBase Study Group. <i>CNS Drugs</i> . 2021 Oct;35(10):1097-1106. doi: 10.1007/s40263-021-00833-w. Epub 2021 Jun 23.	2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrij M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, José Sá M, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. <i>Comput Methods Programs Biomed</i> . 2021 Sep;208:106180. doi: 10.1016/j.cmpb.2021.106180. Epub 2021 May 18.	
Association of Exposure to Particulate Matters and Multiple Sclerosis: A Systematic Review and Meta-Analysis. Lotfi F, Mansourian M, Mirmoayyeb O, Najdaghi S, Shaygannejad V, Esmaeil N. <i>Neuroimmunomodulation</i> . 2022;29(1):21-27. doi: 10.1159/000516559. Epub 2021 Jun 16.	2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.	2021

<p>Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrij M, Lugaresi A, Terzi M, Grammond P, Grand Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Leray E, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. <i>Mult Scler Relat Disord</i>. 2021 Aug;53:103012. doi: 10.1016/j.msard.2021.103012. Epub 2021 May 8.</p>	
<p>Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis. Mirmosayyeb O, Shaygannejad V, Nehzat N, Mohammadi A, Ghajarzadeh M. <i>Int J Prev Med</i>. 2021 Feb 24;12:14. doi: 10.4103/ijpvm.IJPVM_75_20. eCollection 2021.</p>	2021
<p>COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review. Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2021 May 20;8(4):e1001. doi: 10.1212/NXI.0000000000001001. Print 2021 Jul.</p>	2021
<p>Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Barzegar M, Vaheb S, Mirmosayyeb O, Afshari-Safavi A, Nehzat N, Shaygannejad V. <i>Mult Scler Relat Disord</i>. 2021 Jul;52:102947. doi: 10.1016/j.msard.2021.102947. Epub 2021 Apr 11.</p>	
<p>Mizaj assessment in Multiple Sclerosis (MS) patients based on Persian Medicine. Abbasian R, Mojahedi M, Alizadeh M, Khafri S, Ansaripour M, Moosavyzadeh A, Kamali M, Babaeian M, Sourtiji H, Shaygannejad V, Kerdarian H, Rezaeizadeh H. <i>J Complement Integr Med</i>. 2021 May 10. doi: 10.1515/jcim-2020-0428. Online ahead of print.</p>	2021

<p>Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial.</p> <p>Abbasirad F, Shaygannejad V, Hosseinasab F, Mirmosayyeb O, Mahaki B, Moayedi B, Esmaeil N. <i>Int Immunopharmacol.</i> 2021 Aug;97:107715. doi: 10.1016/j.intimp.2021.107715. Epub 2021 Apr 29.</p>	2021
<p>Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage.</p> <p>Shaygannejad V, Mirmosayyeb O, Nehzat N, Ghajarzadeh M. <i>Neurol Sci.</i> 2021 Jul;42(7):2615-2618. doi: 10.1007/s10072-021-05253-8. Epub 2021 Apr 15.</p>	2021
<p>Gene expression profiles of YAP1, TAZ, CRB3, and VDR in familial and sporadic multiple sclerosis among an Iranian population.</p> <p>Khalilian S, Hojati Z, Dehghanian F, Shaygannejad V, Imani SZH, Kheirollahi M, Khorrami M, Mirmosayyeb O. <i>Sci Rep.</i> 2021 Apr 8;11(1):7713. doi: 10.1038/s41598-021-87131-z.</p>	2021
<p>Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis.</p> <p>Barzegar M, Mirmosayeb O, Rezaei M, Bjørklund G, Nehzat N, Afshari-Safavi A, Shaygannejad V. <i>Dysphagia.</i> 2022 Feb;37(1):21-27. doi: 10.1007/s00455-021-10245-z. Epub 2021 Feb 12.</p>	2021
<p>Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.</p> <p>Karimi L, Eskandari N, Shaygannejad V, Zare N, Andalib A, Khanahmad H, Mirmosayyeb O. <i>Iran J Allergy Asthma Immunol.</i> 2020 Aug 25;19(4):416-425. doi: 10.18502/ijaai.v19i4.4116.</p>	2020
<p>Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.</p> <p>Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand'Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J,</p>	2020

<p>Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermode A, Csepany T, Singhal B, Shuey N, Piroaska I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H; MSBase Study Group. <i>Neurology</i>. 2021 Feb 2;96(5):e783-e797. doi: 10.1212/WNL.0000000000011242. Epub 2020 Dec 28.</p>	
<p>Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M. <i>Autoimmun Rev</i>. 2021 Feb;20(2):102727. doi: 10.1016/j.autrev.2020.102727. Epub 2020 Dec 17.</p>	2020
<p>Pregnancy outcome in patients with multiple sclerosis treated with Rituximab: A case-series study. Seyed Ahadi M, Sahraian MA, Baghbanian SM, Azimi A, Shaygannejad V, Anjidani N, Mohammadiani Nejad SE, Izadi S, Beladi Moghadam N, Ayromlou H, Ashtari F, Amiri A, Niknam Z, Asarzadegan F, Mazdeh M, Bayati A, Yousefi Pour GA, Yazdanbakhsh S, Naser Moghadasi A. <i>Mult Scler Relat Disord</i>. 2021 Jan;47:102667. doi: 10.1016/j.msard.2020.102667. Epub 2020 Dec 4.</p>	2020
<p>Frequency of comorbidities in Neuromyelitis Optica spectrum disorder. Barzegar M, Mirmosayyeb O, Nehzat N, Vaheb S, Shaygannejad V, Asgari N. <i>Mult Scler Relat Disord</i>. 2021 Feb;48:102685. doi: 10.1016/j.msard.2020.102685. Epub 2020 Dec 9.</p>	2020
<p>Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients. Shahpouri MM, Barekatin M, Tavakoli M, Mirmosayyeb O, Safaei A, Shaygannejad V. <i>Neurol Res Int</i>. 2020 Nov 22;2020:8874424. doi: 10.1155/2020/8874424. eCollection 2020.</p>	2020
<p>Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis. Barzegar M, Allahdadian S, Mirmosayyeb O, Azarbayejani R, Badihian S, Nehzat N, Daryanavardi S, Barzegar S, Shaygannejad V. <i>Psychol Health Med</i>. 2020 Dec 10:1-11. doi: 10.1080/13548506.2020.1859564. Online ahead of print.</p>	2020

<p>Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.</p> <p>Shaygannejad V, Afshari-Safavi A, Hatef B. <i>Neurol Sci.</i> 2021 Jul;42(7):2891-2901. doi: 10.1007/s10072-020-04905-5. Epub 2020 Nov 20.</p>	2020
<p>Higher Disease and Pain Severity and Fatigue and Lower Balance Skills Are Associated with Higher Prevalence of Falling among Individuals with the Inflammatory Disease of Neuromyelitis Optica Spectrum Disorder (NMOSD).</p> <p>Barzegar M, Sadeghi Bahmani D, Mirmosayyeb O, Azarbajehani R, Afshari-Safavi A, Vaheb S, Nehzat N, Dana A, Shaygannejad V, Motl RW, Brand S. <i>J Clin Med.</i> 2020 Nov 9;9(11):3604. doi: 10.3390/jcm9113604.</p>	2020
<p>The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis.</p> <p>Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. <i>J Clin Neurosci.</i> 2020 Sep;79:33-38. doi: 10.1016/j.jocn.2020.06.021. Epub 2020 Aug 4.</p>	2020
<p>MS Care in Novel Coronavirus 19 Pandemic.</p> <p>Ramezani N, Adibi I, Mirmosayyeb O, Shaygannejad V. <i>Int J Prev Med.</i> 2020 Jul 9;11:98. doi: 10.4103/ijpvm.IJPVM_242_20. eCollection 2020.</p>	2020
<p>Screening neuromyelitis optica patients for COVID-19 infection.</p> <p>Mirmosayyeb O, Vaheb S, Barzegar M, Shaygannejad V, Bonavita S, Ghajarzadeh M. <i>Autoimmun Rev.</i> 2020 Nov;19(11):102669. doi: 10.1016/j.autrev.2020.102669. Epub 2020 Sep 14.</p>	2020
<p>Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.</p> <p>Cheshmavar M, Mirmosayyeb O, Badihian N, Badihian S, Shaygannejad V. <i>Acta Neurol Scand.</i> 2021 Feb;143(2):178-187. doi: 10.1111/ane.13344. Epub 2020 Oct 27.</p>	2020
<p>Upregulation of MTOR, RPS6KB1, and EIF4EBP1 in the whole blood samples of Iranian patients with multiple sclerosis compared to healthy controls.</p> <p>Akbarian F, Tabatabaiefar MA, Shaygannejad V, Shahpouri MM, Badihian N, Sajjadi R, Dabiri A, Jalilian N, Noori-Dalooi MR. <i>Metab Brain Dis.</i> 2020 Dec;35(8):1309-1316. doi: 10.1007/s11011-020-00590-7. Epub 2020 Aug 18.</p>	2020

<p>Comparison of Psychological Difficulties in Patients with Migraine and Epilepsy Using PARADISE-24 Questionnaire.</p> <p>Mirmosayyeb O, Shaygannejad V, Ghajarzadeh M.J Multidiscip Healthc. 2020 Jul 10;13:609-613. doi: 10.2147/JMDH.S260056. eCollection 2020.</p>	2020
<p>Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial.</p> <p>Shahpouri MM, Barekatin M, Tavakoli M, Badihian S, Shaygannejad V.Int J Prev Med. 2020 Jun 19;11:69. doi: 10.4103/ijpvm.IJPVM_154_19. eCollection 2020.</p>	2020
<p>Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?</p> <p>Sadeghpour N, Mirmosayyeb O, Bjørklund G, Shaygannejad V.J Mol Neurosci. 2020 Nov;70(11):1829-1835. doi: 10.1007/s12031-020-01576-x. Epub 2020 Aug 1.</p>	2020
<p>Characteristics of COVID-19 disease in multiple sclerosis patients.</p> <p>Barzegar M, Mirmosayyeb O, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, Vosoughi R.Mult Scler Relat Disord. 2020 Oct;45:102276. doi: 10.1016/j.msard.2020.102276. Epub 2020 Jun 8.</p>	2020
<p>Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.</p> <p>Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, Eichau S, Ozakbas S, Lugaresi A, Prat A, Girard M, Duquette P, Larochele C, Alroughani R, Bergamaschi R, Sola P, Ferraro D, Grammond P, Grand' Maison F, Terzi M, Boz C, Hupperts R, Butzkueven H, Pucci E, Granella F, Van Pesch V, Soysal A, Yamout BI, Lechner-Scott J, Spitaleri D, Ampapa R, Turkoglu R, Iuliano G, Ramo-Tello C, Sanchez-Menoyo JL, Sidhom Y, Gouider R, Shaygannejad V, Prevost J, Altintas A, Fragoso YD, McCombe PA, Petersen T, Slee M, Barnett MH, Vucic S, Van Der Walt A, Kalincik T.Mult Scler. 2021 Apr;27(5):755-766. doi: 10.1177/1352458520926955. Epub 2020 Jun 15.</p>	2020
<p>Pre-pregnancy, obstetric and delivery status in women with neuromyelitis optica spectrum disorder.</p> <p>Ashtari F, Mehdipour R, Shaygannejad V, Asgari N.Mult Scler Relat Disord. 2020 Sep;44:102252. doi: 10.1016/j.msard.2020.102252. Epub 2020 Jun 2.</p>	2020
<p>Quality of life among patients with multiple sclerosis and voiding dysfunction: a cross-sectional study.</p>	2020

Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. BMC Urol. 2020 Jun 3;20(1):62. doi: 10.1186/s12894-020-00590-w.	
Spiritual health in women with multiple sclerosis and its association with self-esteem. Shaygannejad V, Mohamadirizi S. J Educ Health Promot. 2020 Mar 31;9:64. doi: 10.4103/jehp.jehp_144_19. eCollection 2020.	2020
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.	2020
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Barzegar M, Mirmosayyeb O, Nehzat N, Sarrafi R, Khorvash F, Maghzi AH, Shaygannejad V. Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4):e753. doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.	2020
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. Mirmosayyeb O, Brand S, Barzegar M, Afshari-Safavi A, Nehzat N, Shaygannejad V, Sadeghi Bahmani D. J Clin Med. 2020 May 2;9(5):1326. doi: 10.3390/jcm9051326.	2020
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. AlSharoqi IA, Aljumah M, Bohlega S, Boz C, Daif A, El-Koussa S, Inshasi J, Kurtuncu M, Müller T, Retief C, Sahraian MA, Shaygannejad V, Slassi I, Taha K, Zakaria M, Sørensen PS. Neurol Ther. 2020 Jun;9(1):55-66. doi: 10.1007/s40120-020-00187-3. Epub 2020 Apr 15.	2020
Comparison of prevalence rates of restless legs syndrome, self-assessed risks of obstructive sleep apnea, and daytime sleepiness among patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Shaygannejad V, Sadeghi Bahmani D, Soleimani P, Mirmosayyeb O, Barzegar M, Amra B, Brand S. Sleep Med. 2020 Jun;70:97-105. doi: 10.1016/j.sleep.2019.11.1266. Epub 2019 Dec 17.	2020

<p>Evaluation of glucose-6-phosphate dehydrogenase serum level in patients with multiple sclerosis and neuromyelitis optica.</p> <p>Chitsaz N, Dehghani L, Safi A, Esmalian-Afyouni N, Shaygannejad V, Rezvani M, Sohrabi K, Moridi K, Moayednia M. Iran J Neurol. 2019 Oct 7;18(4):150-153.</p>	2020
<p>Modulation of Th17 Proliferation and IL-17A Gene Expression by Acetylated Form of Apigenin in Patients with Multiple Sclerosis.</p> <p>Rahmati M, Ghannadian SM, Kasiri N, Ahmadi L, Motedayyen H, Shaygannejad V, Pourazar A, Alsahebfosoul F, Ganjalikhani Hakemi M, Eskandari N. Immunol Invest. 2021 Feb;50(2-3):216-229. doi: 10.1080/08820139.2020.1726381. Epub 2020 Feb 26.</p>	2020
<p>Sexual dysfunction in women with multiple sclerosis: prevalence and impact on quality of life.</p> <p>Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. BMC Urol. 2020 Feb 21;20(1):15. doi: 10.1186/s12894-020-0581-2.</p>	2020
<p>Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects.</p> <p>Ashtari F, Madanian R, Shaygannejad V, Zarkesh SH, Ghadimi K. Int J Physiol Pathophysiol Pharmacol. 2019 Dec 15;11(6):267-273. eCollection 2019.</p>	2020
<p>The prevalence of lower urinary tract symptoms based on individual and clinical parameters in patients with multiple sclerosis.</p> <p>Nazari F, Shaygannejad V, Mohammadi Sichani M, Mansourian M, Hajhashemi V. BMC Neurol. 2020 Jan 17;20(1):24. doi: 10.1186/s12883-019-1582-1.</p>	2020
<p>Evaluation of cognitive rehabilitation on the cognitive performance in multiple sclerosis: A randomized controlled trial.</p> <p>Shahpouri MM, Barekatalin M, Tavakoli M, Sanaei S, Shaygannejad V. J Res Med Sci. 2019 Dec 23;24:110. doi: 10.4103/jrms.JRMS_124_19. eCollection 2019.</p>	2020
<p>Therapeutic plasma exchange may adjust IL-6 and TGF-β signals in relapsed MS patients peripheral blood.</p> <p>Jamshidian A, Abd-Nikfarjam B, Khademi Z, Shaygannejad V, Salehi M. J Clin Apher. 2020 Apr;35(2):72-78. doi: 10.1002/jca.21755. Epub 2020 Jan 3.</p>	2020

<p>Association Study between Functional Polymorphisms of <i>MMP9</i> Gene Promoter and Multiple Sclerosis Susceptibility in an Iranian Population.</p> <p>Sabbagh S, Nadeali Z, Dehghani L, Shaygannejad V, Rezvani M, Saboori M, Ganji H, Tahani S, Dehghani F, Hosseinzadeh S, Marzbani E, Shafiei P. Iran J Public Health. 2019 Sep;48(9):1697-1703.</p>	2019
<p>Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.</p> <p>Fattahi M, Eskandari N, Sotoodehnejadnematalahi F, Shaygannejad V, Kazemi M. Cell J. 2020 Apr;22(1):92-95. doi: 10.22074/cellj.2020.6486. Epub 2019 Sep 8.</p>	2019
<p>Elevated serum level of IL-4 in neuromyelitis optica and multiple sclerosis patients.</p> <p>Tahani S, Dehghani L, Jahanbani-Ardakani H, Shaygannejad V, Fazli A, Hamidavi A, Eskandari N. J Immunoassay Immunochem. 2019;40(5):555-563. doi: 10.1080/15321819.2019.1655649. Epub 2019 Aug 19.</p>	2019
<p>MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.</p> <p>Fattahi M, Rezaei N, Nematalahi FS, Shaygannejad V, Fouladi S, Karimi L, Fathi F, Dehghani L, Mirmosayyeb O, Eskandari N. Mult Scler Relat Disord. 2019 Oct;35:241-245. doi: 10.1016/j.msard.2019.07.034. Epub 2019 Jul 31.</p>	2019
<p>Novel mutation in <i>HTRAI</i> in a family with diffuse white matter lesions and inflammatory features.</p> <p>Ziaei A, Xu X, Dehghani L, Bonnard C, Zellner A, Jin Ng AY, Tohari S, Venkatesh B, Haffner C, Reversade B, Shaygannejad V, Pouladi MA. Neurol Genet. 2019 Jul 8;5(4):e345. doi: 10.1212/NXG.0000000000000345. eCollection 2019 Aug.</p>	2019
<p>Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city.</p> <p>Ashtari F, Mehdipour R, Shaygannejad V, Mansourian M. Mult Scler Relat Disord. 2019 Sep;34:77-82. doi: 10.1016/j.msard.2019.06.013. Epub 2019 Jun 20.</p>	2019
<p>Management of seizures in patients with multiple sclerosis; an Iranian consensus.</p>	2019

<p>Asadi-Pooya AA, Sahraian MA, Sina F, Baghbanian SM, Habibabadi JM, Shaygannejad V, Asadollahi M, Karvigh SA, Moghadasi AN, Nikseresht A, Motamedi M. <i>Epilepsy Behav.</i> 2019 Jul;96:244-248. doi: 10.1016/j.yebeh.2019.04.032.</p>	
<p>In Patients With Multiple Sclerosis, Both Objective and Subjective Sleep, Depression, Fatigue, and Paresthesia Improved After 3 Weeks of Regular Exercise.</p> <p>Sadeghi Bahmani D, Kesselring J, Papadimitriou M, Bansi J, Pühse U, Gerber M, Shaygannejad V, Holsboer-Trachsler E, Brand S. <i>Front Psychiatry.</i> 2019 May 3;10:265. doi: 10.3389/fpsy.2019.00265. eCollection 2019.</p>	2019
<p>Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls.</p> <p>Barzegar M, Sadeghi Bahmani D, Nehzat N, Kiani M, Hashemi N, Mirmosayyeb O, Brand S, Shaygannejad V. <i>Mult Scler Relat Disord.</i> 2019 Jul;32:81-87. doi: 10.1016/j.msard.2019.04.008. Epub 2019 Apr 12.</p>	2019
<p>Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients.</p> <p>Alidadiani P, Eskandari N, Shaygannejad V, Dabiri A, Manian M, Jahanbani-Ardakani H, Mirmosayyeb O. <i>Biomol Concepts.</i> 2019 Apr 11;10(1):62-67. doi: 10.1515/bmc-2019-0007.</p>	2019
<p>Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (MS) Patients In Vitro.</p> <p>Shariati M, Shaygannejad V, Abbasirad F, Hosseininasab F, Kazemi M, Mirmosayyeb O, Esmail N. <i>Inflammation.</i> 2019 Aug;42(4):1203-1214. doi: 10.1007/s10753-019-00980-9.</p>	2019
<p>Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.</p> <p>Brown JW, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slemmon M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. <i>JAMA.</i> 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.</p>	2019
<p>Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.</p>	2019

<p>Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrij M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13.</p>	
<p>Genetic Variation in Intergenic and Exonic miRNA Sequence and Risk of Multiple Sclerosis in the Isfahan Patients.</p> <p>Golshani Z, Hojati Z, Sharifzadeh A, Shaygannejad V, Jafarinia M.Iran J Allergy Asthma Immunol. 2018 Oct 14;17(5):477-484.</p>	2018
<p>Promising effect of rapamycin on multiple sclerosis.</p> <p>Bagherpour B, Salehi M, Jafari R, Bagheri A, Kiani-Esfahani A, Edalati M, Kardi MT, Shaygannejad V.Mult Scler Relat Disord. 2018 Nov;26:40-45. doi: 10.1016/j.msard.2018.08.009. Epub 2018 Aug 10.</p>	2018
<p>The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder.</p> <p>Mehdipour-Dastjerdi R, Ashtari F, Shaygannejad V, Mansourian M, Safaei A.Iran J Neurol. 2018 Apr 4;17(2):58-63.</p>	2018
<p>Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran.</p> <p>Salari M, Mirmosayyeb O, Etemadifar M, Shaygannejad V, Khorvash F, Najafi MR, Ashtari F, Chitsaz A.Iran J Neurol. 2018 Jan 5;17(1):6-10.</p>	2018
<p>Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated from Newly Diagnosed and IFN-β1b-Treated MS Patients.</p> <p>Navabi F, Shaygannejad V, Abbasirad F, Vaez E, Hosseininasab F, Kazemi M, Mirmosayyeb O, Alsahebfosoul F, Esmaeil N.Inflammation. 2019 Feb;42(1):54-63. doi: 10.1007/s10753-018-0872-x.</p>	2018
<p>Association between Sun Exposure, Vitamin D Intake, Serum Vitamin D Level, and Immunoglobulin G Level in Patients with Neuromyelitis Optica Spectrum Disorder.</p>	2018

Shaygannejad V, Maljaei MB, Bank SS, Mirmosayyeb O, Maracy MR, Askari G. <i>Int J Prev Med</i> . 2018 Aug 14;9:68. doi: 10.4103/ijpvm.IJPVM_45_16. eCollection 2018.	
Lower extremity deep venous thrombosis in a multiple sclerosis patient on dimethyl fumarate. Mirmosayyeb O, Fayyazi E, Shaygannejad V, Esmaeil N. <i>Mult Scler Relat Disord</i> . 2018 Oct;25:196. doi: 10.1016/j.msard.2018.07.037. Epub 2018 Jul 21.	2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, Girard M, Duquette P, Grand'Maison F, Grammond P, Sola P, Ferraro D, Ramo-Tello C, Trojano M, Sleen M, Shaygannejad V, Boz C, Lechner-Scott J, Van Pesch V, Pucci E, Solaro C, Verheul F, Terzi M, Granella F, Spitaleri D, Alroughani R, Jun JK, Fambias A, Van der Walt A, Butzkueven H, Kalincik T; MSBase Study Group. <i>JAMA Neurol</i> . 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.	2018
High Frequency of Tc22 and Th22 Cells in Myasthenia Gravis Patients and Their Significant Reduction after Thymectomy. Robot-Jazi B, Hosseini M, Shaygannejad V, Nafissi S, Rezaei A, Mansourain M, Mirmosayyeb O, Esmaeil N. <i>Neuroimmunomodulation</i> . 2018;25(2):80-88. doi: 10.1159/000490855. Epub 2018 Aug 2.	2018
Neuromyelitis optica spectrum disorder and menstruation. Badihian S, Manouchehri N, Mirmosayyeb O, Ashtari F, Shaygannejad V. <i>Rev Neurol (Paris)</i> . 2018 Dec;174(10):716-721. doi: 10.1016/j.neurol.2018.01.373. Epub 2018 Jul 23.	2018
Stability of Mental Toughness, Sleep Disturbances, and Physical Activity in Patients With Multiple Sclerosis (MS)-A Longitudinal and Pilot Study. Sadeghi Bahmani D, Esmaeili L, Shaygannejad V, Gerber M, Kesselring J, Lang UE, Holsboer-Trachsler E, Brand S. <i>Front Psychiatry</i> . 2018 May 17;9:182. doi: 10.3389/fpsy.2018.00182. eCollection 2018.	2018
Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran.	2018

Barzegar M, Badihian S, Mirmosayyeb O, Ashtari F, Jamadi M, Emami S, Jahani L, Safavi A, Shaygannejad V. <i>Mult Scler Relat Disord</i> . 2018 May;22:161-165. doi: 10.1016/j.msard.2018.04.009. Epub 2018 Apr 14.	
OX40 Gene and Serum Protein Expression Profiles in Patients with Parkinson's Disease. Seyedjoodaki A, Alsahebfosoul F, Eskandari N, Shaygannejad V, Salehi M, Kazemi M, Manian M, Mirmosayyeb O, Taghi Kardi M. <i>Cell J</i> . 2018 Jul;20(2):177-182. doi: 10.22074/cellj.2018.5038. Epub 2018 Mar 18.	2018
The interplay of multiple sclerosis and menstrual cycle: Which one affects the other one? Mirmosayyeb O, Badihian S, Manouchehri N, Basiri AK, Barzegar M, Esmail N, Fayyazi E, Shaygannejad V. <i>Mult Scler Relat Disord</i> . 2018 Apr;21:46-50. doi: 10.1016/j.msard.2018.01.020. Epub 2018 Feb 2.	2018
Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis. Hosseini M, Robot-Jazi B, Shaygannejad V, Naffisi S, Mirmossayeb O, Rezaei A, Mansourian M, Esmail N. <i>Neuroimmunomodulation</i> . 2017;24(4-5):264-270. doi: 10.1159/000486037. Epub 2018 Feb 8.	2018
Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod. Manouchehri N, Mirmosayyeb O, Badihian S, Shaygannejad V. <i>Mult Scler Relat Disord</i> . 2018 Jan;19:121-123. doi: 10.1016/j.msard.2017.11.012. Epub 2017 Nov 22.	2018
The Effect of Emotional Intelligence Training on Self-efficacy in Women with Multiple Sclerosis. Mehrabi Z, Nazari F, Mehrabi T, Shaygannejad V. <i>Iran J Nurs Midwifery Res</i> . 2017 Nov-Dec;22(6):421-426. doi: 10.4103/ijnmr.IJNMR_145_16.	2017
Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations. Sahraian MA, Moghadasi AN, Azimi AR, Asgari N, H Akhoundi F, Abolfazli R, Alaie S, Ashtari F, Ayromlou H, Baghbanian SM, Moghadam NB, Fatehi F, Foroughipour M, Langroodi HG, Majdinasab N, Nickseresht A, Nourian A, Shaygannejad V, Torabi HR. <i>Mult</i>	2017

Scler Relat Disord. 2017 Nov;18:144-151. doi: 10.1016/j.msard.2017.09.015. Epub 2017 Sep 25.	
Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial. Zandi-Esfahan S, Fazeli M, Shaygannejad V, Hasheminia J, Badihian S, Aghayerashti M, Maghzi H. Clin Neurol Neurosurg. 2017 Dec;163:173-178. doi: 10.1016/j.clineuro.2017.10.004. Epub 2017 Oct 3.	2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group. Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.	2017
Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. J Neurol. 2017 Sep;264(9):2003-2009. doi: 10.1007/s00415-017-8590-0. Epub 2017 Aug 22.	2017
A comparison the effects of reflexology and relaxation on the psychological symptoms in women with multiple sclerosis. Soheili M, Nazari F, Shaygannejad V, Valiani M. J Educ Health Promot. 2017 Apr 19;6:11. doi: 10.4103/jehp.jehp_166_14. eCollection 2017.	2017
The effect of electronic education on knowledge of patients with multiple sclerosis. Mohamadirizi S, Shaygannejad V, Mohamadirizi S, Tolou-Ghamari Z. J Educ Health Promot. 2017 Apr 19;6:10. doi: 10.4103/jehp.jehp_144_14. eCollection 2017.	2017
The survey of mindfulness in multiple sclerosis patients and its association with attachment style.	2017

Mohamadirizi S, Shaygannejad V, Mohamadirizi S.J Educ Health Promot. 2017 Apr 19;6:7. doi: 10.4103/jehp.jehp_114_14. eCollection 2017.	
Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. Ashtari F, Safaei A, Shaygannejad V, Najafi MA, Vesal S.J Res Med Sci. 2017 Mar 15;22:41. doi: 10.4103/1735-1995.202142. eCollection 2017.	2017
Prognostic indicators in pediatric clinically isolated syndrome. Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry. Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.	2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Boz C, Grammond P, Terzi M, Singhal B, Alroughani R, Petersen T, Ramo C, Oreja-Guevara C, Spitaleri D, Shaygannejad V, Butzkueven H, Kalincik T, Jokubaitis V, Slee M, Fernandez Bolaños R, Sanchez-Menoyo JL, Pucci E, Granella F, Lechner-Scott J, Iuliano G, Hughes S, Bergamaschi R, Taylor B, Verheul F, Edite Rio M, Amato MP, Sajedi SA, Majdinasab N, Van Pesch V, Sormani MP, Trojano M. Mult Scler. 2018 Apr;24(5):642-652. doi: 10.1177/1352458517703800. Epub 2017 Apr 6.	2017
Consanguinity and multiple sclerosis susceptibility: A case control study. Maghzi H, Shaygannejad V, Minagar A, Hassanzadeh A, Maghzi AH. Mult Scler Relat Disord. 2016 Nov;10:179-180. doi: 10.1016/j.msard.2016.09.013. Epub 2016 Sep 30.	2016
Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J,	2016

<p>Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group. <i>J Neurol Neurosurg Psychiatry</i>. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.</p>	
<p>Mental toughness, sleep disturbances, and physical activity in patients with multiple sclerosis compared to healthy adolescents and young adults.</p> <p>Sadeghi Bahmani D, Gerber M, Kalak N, Lemola S, Clough PJ, Calabrese P, Shaygannejad V, Pühse U, Holsboer-Trachsler E, Brand S. <i>Neuropsychiatr Dis Treat</i>. 2016 Jun 27;12:1571-9. doi: 10.2147/NDT.S111208. eCollection 2016.</p>	2016
<p>The environmental risk factors in multiple sclerosis susceptibility: A case-control study.</p> <p>Shaygannejad V, Rezaie N, Paknahad Z, Ashtari F, Maghzi H. <i>Adv Biomed Res</i>. 2016 Jun 8;5:98. doi: 10.4103/2277-9175.183665. eCollection 2016.</p>	2016
<p>The effect of electronic package on satisfaction in multiple sclerosis patients.</p> <p>Mohamadirizi S, Shaygannejad V, Mohamadirizi S, Khosrawi S. <i>Adv Biomed Res</i>. 2016 May 30;5:89. doi: 10.4103/2277-9175.183143. eCollection 2016.</p>	2016
<p>Co-occurrence of multiple sclerosis and Parkinson disease.</p> <p>Shaygannejad V, Shirmardi M, Dehghani L, Maghzi H. <i>Adv Biomed Res</i>. 2016 Apr 21;5:75. doi: 10.4103/2277-9175.180993. eCollection 2016.</p>	2016
<p>Contribution of different relapse phenotypes to disability in multiple sclerosis.</p> <p>Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Duquette P, Girard M, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Sola P, Shaygannejad V, Hupperts R, Alroughani R, Oreja-Guevara C, Pucci E, Boz C, Lechner-Scott J, Bergamaschi R, Van Pesch V, Iuliano G, Ramo C, Taylor B, Slee M, Spitaleri D, Granella F, Verheul F, McCombe P, Hodgkinson S, Amato MP, Vucic S, Gray O, Cristiano E, Barnett M, Sanchez Menoyo JL, van Munster E, Saladino ML, Olascoaga J, Prevost J, Deri N, Shaw C, Singhal B, Moore F, Rozsa C, Shuey N, Skibina O, Kister I, Petkovska-Boskova T, Ampapa R, Kermodé A, Butzkueven H, Jokubaitis V, Kalincik T; MSBase Study Group. <i>Mult Scler</i>. 2017 Feb;23(2):266-276. doi: 10.1177/1352458516643392. Epub 2016 Jul 11.</p>	2016

<p>Vasomotor reactivity comparison in multiple sclerosis patients with white matter lesions and nonmultiple sclerosis subjects with white matter lesions in brain magnetic resonance imaging.</p> <p>Khorvash F, Masaeli A, Shaygannejad V, Saadatnia M. Adv Biomed Res. 2016 Feb 8;5:23. doi: 10.4103/2277-9175.175916. eCollection 2016.</p>	2016
<p>Yoga intervention on blood NO in female migraineurs.</p> <p>Boroujeni MZ, Marandi SM, Esfarjani F, Sattar M, Shaygannejad V, Javanmard SH. Adv Biomed Res. 2015 Dec 31;4:259. doi: 10.4103/2277-9175.172995. eCollection 2015.</p>	2015
<p>The Effect of Plasma Exchange on the Expression of FOXP3 and RORC2 in Relapsed Multiple Sclerosis Patients.</p> <p>Jamshidian A, Kazemi M, Shaygannejad V, Salehi M. Iran J Immunol. 2015 Dec;12(4):311-8.</p>	2015
<p>Transocular Doppler and optic nerve sheath diameter monitoring to detect intracranial hypertension.</p> <p>Karami M, Shirazinejad S, Shaygannejad V, Shirazinejad Z. Adv Biomed Res. 2015 Oct 22;4:231. doi: 10.4103/2277-9175.167900. eCollection 2015.</p>	2015
<p>Psychological well-being in people with multiple sclerosis in an Iranian population.</p> <p>Dehnavi SR, Heidarian F, Ashtari F, Shaygannejad V. J Res Med Sci. 2015 Jun;20(6):535-9. doi: 10.4103/1735-1995.165942.</p>	2015
<p>A comparison of the effects of reflexology and relaxation on pain in women with multiple sclerosis.</p> <p>Nazari F, Soheili M, Hosseini S, Shaygannejad V. J Complement Integr Med. 2016 Mar;13(1):65-71. doi: 10.1515/jcim-2015-0046.</p>	2015
<p>Preliminary study on patients located at the Kashani/Isfahan Hospital with multiple sclerosis between the years 2011 and 2013.</p> <p>Tolou-Ghamari Z, Ashtari F, Shaygannejad V, Palizban AA. Adv Biomed Res. 2015 Aug 10;4:165. doi: 10.4103/2277-9175.162542. eCollection 2015.</p>	2015
<p>Comparison of emotional and non-emotional word repetitions in patients with aphasia.</p> <p>Bakhtiyari J, Khatoonabadi SA, Dadgar H, Bakhtiari BM, Khosravizadeh P, Shaygannejad V. Adv Biomed Res. 2015 Aug 10;4:164. doi: 10.4103/2277-9175.162540. eCollection 2015.</p>	2015

<p>Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.</p> <p>Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, Girard M, Grand'Maison F, Hupperts R, Grammond P, Oreja-Guevara C, Petersen T, Bergamaschi R, Giuliani G, Barnett M, van Pesch V, Amato MP, Iuliano G, Fiol M, Slee M, Verheul F, Cristiano E, Fernandez-Bolanos R, Saladino ML, Rio ME, Cabrera-Gomez J, Butzkueven H, van Munster E, Den Braber-Moerland L, La Spitaleri D, Lugaresi A, Shaygannejad V, Gray O, Deri N, Alroughani R, Lechner-Scott J. PLoS One. 2015 Jun 5;10(6):e0122686. doi: 10.1371/journal.pone.0122686. eCollection 2015.</p>	2015
<p>Comparing the effects of reflexology and relaxation on fatigue in women with multiple sclerosis.</p> <p>Nazari F, Shahreza MS, Shaygannejad V, Valiani M. Iran J Nurs Midwifery Res. 2015 Mar-Apr;20(2):200-4.</p>	2015
<p>Cytokines gene expression in newly diagnosed multiple sclerosis patients.</p> <p>Hasheminia SJ, Tolouei S, Zarkesh-Esfahani SH, Shaygannejad V, Shirzad HA, Torabi R, Hashem Zadeh Chaloshatory M. Iran J Allergy Asthma Immunol. 2015 Apr;14(2):208-16.</p>	2015
<p>Clinical utility of residual latency in ulnar neuropathy at elbow: Is there any correlation?</p> <p>Khosrawi S, Dehghan F, Shaygannejad V. Adv Biomed Res. 2015 Jan 30;4:21. doi: 10.4103/2277-9175.150386. eCollection 2015.</p>	2015
<p>A Single-subject Study to Examine the Effects of Constrained-induced Aphasia Therapy on Naming Deficit.</p> <p>Kavian S, Khatoonabadi AR, Ansari NN, Saadati M, Shaygannejad V. Int J Prev Med. 2014 Jun;5(6):782-6.</p>	2014
<p>Correlation of midkine serum level with pro- and anti-inflammatory cytokines in multiple sclerosis.</p> <p>Shaygannejad V, Montazeri S, Jamshidian A, Tahani S, Gharagozloo M, Ashtari F, Vesal S, Hasheminia SJ, Dehghani L. Iran J Immunol. 2014 Jun;11(2):134-8.</p>	2014
<p>Toll like receptor 2 and 4 expression in peripheral blood mononuclear cells of multiple sclerosis patients.</p>	2014

Hasheminia SJ, Zarkesh-Esfahani SH, Tolouei S, Shaygannejad V, Shirzad H, Hashemzadeh Chaleshtory M. Iran J Immunol. 2014 Jun;11(2):74-83.	
Preventive Effects of a Three-month Yoga Intervention on Endothelial Function in Patients with Migraine. Naji-Esfahani H, Zamani M, Marandi SM, Shaygannejad V, Javanmard SH. Int J Prev Med. 2014 Apr;5(4):424-9.	2014
Islamic fasting and multiple sclerosis. Jahromi SR, Sahraian MA, Ashtari F, Ayromlou H, Etemadifar M, Ghaffarpour M, Mohammadianinejad E, Nafissi S, Nickseresht A, Shaygannejad V, Togha M, Torabi HR, Ziaie S. BMC Neurol. 2014 Mar 22;14:56. doi: 10.1186/1471-2377-14-56.	2014
Multiple sclerosis or neurological manifestations of Celiac disease. Shaygannejad V, Ghasemi M, Mirmohamadsadeghi M. Adv Biomed Res. 2013 Mar 30;2:38. doi: 10.4103/2277-9175.109734. eCollection 2013.	2013
Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon. Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V. J Korean Med Sci. 2013 Dec;28(12):1801-6. doi: 10.3346/jkms.2013.28.12.1801. Epub 2013 Nov 26.	2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. Brain. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18.	2013
The psychometric properties of the persian migraine-specific quality of life questionnaire version 2.1 in episodic and chronic migraines. Zandifar A, Masjedi SS, Haghdoost F, Asgari F, Manouchehri N, Banihashemi M, Najafi MR, Ghorbani A, Zolfaghari B, Gholamrezaei A, Shaygannejad V, Saadatnia	2013

M.ScientificWorldJournal. 2013 Aug 27;2013:950245. doi: 10.1155/2013/950245. eCollection 2013.	
Brain radiation and possible presentation of multiple sclerosis. Shaygannejad V, Zare M, Maghzi H, Emami P.J Res Med Sci. 2013 Mar;18(Suppl 1):S93-5.	2013
Seizure characteristics in multiple sclerosis patients. Shaygannejad V, Ashtari F, Zare M, Ghasemi M, Norouzi R, Maghzi H.J Res Med Sci. 2013 Mar;18(Suppl 1):S74-7.	2013
Oral prednisolone in the treatment of cervical radiculopathy: A randomized placebo controlled trial. Ghasemi M, Masaeli A, Rezvani M, Shaygannejad V, Golabchi K, Norouzi R.J Res Med Sci. 2013 Mar;18(Suppl 1):S43-6.	2013
The value of provocative tests in diagnosis of cervical radiculopathy. Ghasemi M, Golabchi K, Mousavi SA, Asadi B, Rezvani M, Shaygannejad V, Salari M.J Res Med Sci. 2013 Mar;18(Suppl 1):S35-8.	2013
Evaluation of neural gene expression in serum treated embryonic stem cells in Alzheimer's patients. Dehghani L, Hashemi-Beni B, Poorazizi E, Khorvash F, Shaygannejad V, Sedghi M, Vesal S, Meamar R.J Res Med Sci. 2013 Mar;18(Suppl 1):S20-3.	2013
The relation between Vitamin D status with fatigue and depressive symptoms of multiple sclerosis. Ashtari F, Ajalli M, Shaygannejad V, Akbari M, Hovsepian S.J Res Med Sci. 2013 Mar;18(3):193-7.	2013
Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. Jamshidian A, Shaygannejad V, Pourazar A, Zarkesh-Esfahani SH, Gharagozloo M.J Neuroimmunol. 2013 Sep 15;262(1-2):106-12. doi: 10.1016/j.jneuroim.2013.06.007. Epub 2013 Jul 9.	2013
Preliminary investigation of economics issues in hospitalized patients with stroke. Tolou-Ghamari Z, Shaygannejad V, Khorvash F.Int J Prev Med. 2013 May;4(Suppl 2):S338-42.	2013

<p>Study of type a and B behavior patterns in patients with multiple sclerosis in an Iranian population.</p> <p>Shaygannejad V, Dehnavi SR, Ashtari F, Karimi S, Dehghani L, Meamar R, Tolou-Ghamari Z. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S279-83.</p>	2013
<p>Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital.</p> <p>Tolou-Ghamari Z, Shaygannejad V, Ashtari F. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S274-8.</p>	2013
<p>Olanzapine versus haloperidol: which can control stuttering better?</p> <p>Shaygannejad V, Khatoonabadi SA, Shafiei B, Ghasemi M, Fatehi F, Meamar R, Dehghani L. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S270-3.</p>	2013
<p>Can vitamin d suppress endothelial cells apoptosis in multiple sclerosis patients?</p> <p>Dehghani L, Meamar R, Etemadifar M, Sheshde ZD, Shaygannejad V, Sharifkhah M, Tahani S. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S211-5.</p>	2013
<p>The effect of pioglitazone on the Alzheimer's disease-induced apoptosis in human umbilical vein endothelial cells.</p> <p>Dehghani L, Meamar R, Askari G, Khorvash F, Shaygannejad V, Pour AF, Javanmard SH. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S205-10.</p>	2013
<p>Restless legs syndrome in Iranian multiple sclerosis patients: a case-control study.</p> <p>Shaygannejad V, Ardestani PE, Ghasemi M, Meamar R. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S189-93.</p>	2013
<p>The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study.</p> <p>Ghorbani A, Salari M, Shaygannejad V, Norouzi R. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S180-4.</p>	2013
<p>What is the Real Fate of Vitamin D in Multiple Sclerosis?</p> <p>Shaygannejad V, Tolou-Ghamari Z. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S159-64.</p>	2013
<p>A literature review on the efficacy and safety of botulinum toxin: an injection in post-stroke spasticity.</p> <p>Ghasemi M, Salari M, Khorvash F, Shaygannejad V. <i>Int J Prev Med.</i> 2013 May;4(Suppl 2):S147-58.</p>	2013
<p>Stem cell therapy in stroke: a review literature.</p>	2013

Meamar R, Dehghani L, Ghasemi M, Khorvash F, Shaygannejad V. <i>Int J Prev Med</i> . 2013 May;4(Suppl 2):S139-46.	
Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. Shaygannejad V, Janghorbani M, Vaezi A, Haghighi S, Golabchi K, Heshmatipour M. <i>Neurol Res</i> . 2013 Jul;35(6):636-41. doi: 10.1179/1743132813Y.0000000200. Epub 2013 Apr 12.	2013
Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Shaygannejad V, Ashtari F, Alinaghian M, Norouzi R, Salari M, Fatehi F. <i>Clin Neuropharmacol</i> . 2013 Jan-Feb;36(1):1-3. doi: 10.1097/WNF.0b013e3182764f91.	2013
Color blindness among multiple sclerosis patients in Isfahan. Shaygannejad V, Golabchi K, Dehghani A, Ashtari F, Haghighi S, Mirzendehtdel M, Ghasemi M. <i>J Res Med Sci</i> . 2012 Mar;17(3):254-7.	2012
Is the Iranian revolution to blame for the increasing incidence of multiple sclerosis in Iran? Maghzi AH, Sahraian MA, Shaygannejad V, Minagar A. <i>Neuroepidemiology</i> . 2013;40(1):68-9. doi: 10.1159/000341848. Epub 2012 Oct 11.	2012
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H. <i>Neurol Res</i> . 2012 Nov;34(9):854-8. doi: 10.1179/1743132812Y.0000000081. Epub 2012 Sep 12.	2012
Multiple sclerosis in Sistan and Baloochestan, South East Iran. Maghzi AH, Sahraian MA, Maghzi H, Shaygannejad V. <i>Clin Neurol Neurosurg</i> . 2013 Jun;115(6):847-8. doi: 10.1016/j.clineuro.2012.08.014. Epub 2012 Aug 22.	2012
Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. <i>Mult Scler Int</i> . 2012;2012:452541. doi: 10.1155/2012/452541. Epub 2012 Apr 11.	2012
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.	2012

Basiri K, Etemadifar M, Derakhshan F, Ashtari F, Shaygannejad V, Fatehi Z, Maghzi AH, Fatehi F. <i>Acta Med Iran</i> . 2012;50(2):97-100.	
The effects of sodium valproate with fish oil supplementation or alone in migraine prevention: A randomized single-blind clinical trial. Tajmirriahi M, Soheliipour M, Basiri K, Shaygannejad V, Ghorbani A, Saadatnia M. <i>Iran J Neurol</i> . 2012;11(1):21-4.	2012
Optical coherence tomography versus visual evoked potential in multiple sclerosis patients. Fatehi F, Shaygannejad V, Mehr LK, Dehghani A. <i>Iran J Neurol</i> . 2012;11(1):12-5.	2012
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. <i>J Neurol Neurosurg Psychiatry</i> . 2012 Mar;83(3):305-10. doi: 10.1136/jnnp-2011-301051. Epub 2011 Dec 28.	2012
Myasthenia gravis as a presenting feature in a patient with lung cancer: A case report. Shaygannejad V, Ghasemi M, Rajaei Z. <i>J Res Med Sci</i> . 2011 Feb;16(2):229-32.	2011
A Comparative Study of 25 (OH) Vitamin D Serum Levels in Patients with Multiple Sclerosis and Control Group in Isfahan, Iran. Shaygannejad V, Golabchi K, Haghighi S, Dehghan H, Moshayedi A. <i>Int J Prev Med</i> . 2010 Summer;1(3):195-201.	2010
Does early-onset multiple sclerosis differ from adult-onset form in Iranian people. Ashtari F, Shaygannejad V, Farajzadegan Z, Amin A. <i>J Res Med Sci</i> . 2010 Mar;15(2):94-9.	2010
Is Chiari malformation a cause of systemic hypertension and sinus bradycardia? A case report and literature review. Ghasemi M, Golabchi K, Shaygannejad V, Rezvani M. <i>J Res Med Sci</i> . 2011 Jan;16(1):115-8.	2010

<p>Effects of adjunct glucosamine sulfate on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized, placebo-controlled trial.</p> <p>Shaygannejad V, Janghorbani M, Savoj MR, Ashtari F. <i>Neurol Res.</i> 2010 Nov;32(9):981-5. doi: 10.1179/016164110X12656393664964. Epub 2010 Mar 10.</p>	2010
<p>Does amantadine have favourable effects on fatigue in Persian patients suffering from multiple sclerosis?</p> <p>Ashtari F, Fatehi F, Shaygannejad V, Chitsaz A. <i>Neurol Neurochir Pol.</i> 2009 Sep-Oct;43(5):428-32.</p>	2009
<p>Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation.</p> <p>Chitsaz A, Janghorbani M, Shaygannejad V, Ashtari F, Heshmatipour M, Freeman J. <i>Clin J Pain.</i> 2009 May;25(4):281-5. doi: 10.1097/AJP.0b013e318190862b.</p>	2009
<p>Short-term effects of prolonged fasting on multiple sclerosis.</p> <p>Saadatnia M, Etemadifar M, Fatehi F, Ashtari F, Shaygannejad V, Chitsaz A, Maghzi AH. <i>Eur Neurol.</i> 2009;61(4):230-2. doi: 10.1159/000197108. Epub 2009 Jan 29.</p>	2009
<p>Effects of rivastigmine on memory and cognition in multiple sclerosis.</p> <p>Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. <i>Can J Neurol Sci.</i> 2008 Sep;35(4):476-81. doi: 10.1017/s0317167100009148.</p>	2008
<p>Prevalence of multiple sclerosis in Isfahan, Iran.</p> <p>Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. <i>Neuroepidemiology.</i> 2006;27(1):39-44. doi: 10.1159/000094235. Epub 2006 Jun 27.</p>	2006
<p>Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study.</p> <p>Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. <i>Headache.</i> 2006 Apr;46(4):642-8. doi: 10.1111/j.1526-4610.2006.00413.x.</p>	2006

Book Chapters:

- 1- Successful living with Multiple sclerosis
- 2- Successful living with Devic's disease
- 3- Diagnosis and Treatment of Headache
- 4- Neurological Diseases

5- Air Pollution and Human Health (In persian)

Theses:

- More than 65 theses with neurological residents, medical students and also with PhD by research students.